SABS (SAB Biotherapeutics) Moat Score: 4/10 (As of Jun. 29, 2026)


SABS SAB Biotherapeutics Inc SABS
26 GF Score
Price $3.80
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics Moat Score?

SAB Biotherapeutics SABS -1.81% 26 Moat Score is 4 as of Jun. 29, 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, SAB Biotherapeutics ranks better than 88.79% on this metric.

SAB Biotherapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

SAB Biotherapeutics has Narrow Moat: SAB Biotherapeutics has a modest moat with some valuable intellectual property and R&D capabilities. However, it operates in a competitive biotech industry with significant challenges.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes SAB Biotherapeutics might have Narrow Moat - Discernible but modest moat.

SAB Biotherapeutics  (NAS:SABS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

SAB Biotherapeutics Moat Score Related Terms

SABS vs SRZN, GLSI, ZNTL: Moat Score Comparison

For the Biotechnology subindustry, SAB Biotherapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SAB Biotherapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where SAB Biotherapeutics's Moat Score falls into.


SABS
26GF Score
SAB Biotherapeutics Inc SABS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
SAB Biotherapeutics (SABS) has a Moat Score of 4 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, SAB Biotherapeutics ranks #157 out of 1401 companies in the Biotechnology industry, placing it in the top 11.2%.
Is SAB Biotherapeutics' Moat Score too high?
SAB Biotherapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. SAB Biotherapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, SAB Biotherapeutics ranks #157 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' Moat Score compare to SRZN and GLSI?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #157 out of 1401 companies for Moat Score. This places SAB Biotherapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. SAB Biotherapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SAB Biotherapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SAB Biotherapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current Moat Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score

Get the complete analysis for SABS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.80
Price